Baird Maintains Outperform on Medpace Hldgs, Raises Price Target to $454
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Eric Coldwell has maintained an Outperform rating on Medpace Holdings (MEDP) and increased the price target from $446 to $454.

April 24, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Eric Coldwell reaffirmed an Outperform rating on Medpace Holdings and raised the price target to $454.
The reaffirmation of the Outperform rating and increase in price target by Baird analyst Eric Coldwell is a strong positive signal for Medpace Holdings. This suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100